1. Cancer Biology

KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D

  1. Sawan Kumar Jha
  2. Khushbu Rauniyar
  3. Ewa Chronowska
  4. Kenny Mattonet
  5. Eunice Wairimu Maina
  6. Hannu Koistinen
  7. Ulf-Håkan Stenman
  8. Kari Alitalo
  9. Michael Jeltsch  Is a corresponding author
  1. University of Helsinki, Finland
  2. Max Planck Institute for Heart and Lung Research, Germany
  3. Wihuri Research Institute, Finland
https://doi.org/10.7554/eLife.44478
Share this article
Cite this article
  1. Sawan Kumar Jha
  2. Khushbu Rauniyar
  3. Ewa Chronowska
  4. Kenny Mattonet
  5. Eunice Wairimu Maina
  6. Hannu Koistinen
  7. Ulf-Håkan Stenman
  8. Kari Alitalo
  9. Michael Jeltsch
(2019)
KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
eLife 8:e44478.
https://doi.org/10.7554/eLife.44478
  2. Download BibTeX
  3. Download .RIS

Abstract

Vascular endothelial growth factor-C (VEGF-C) acts primarily on endothelial cells, but also on non-vascular targets, e.g. in the CNS and immune system. Here we describe a novel, unique VEGF-C form in the human reproductive system produced via cleavage by kallikrein-related peptidase 3 (KLK3), aka prostate-specific antigen (PSA). KLK3 activated VEGF-C specifically and efficiently through cleavage at a novel N-terminal site. We detected VEGF-C in seminal plasma, and sperm liquefaction occurred concurrently with VEGF-C activation, which was enhanced by collagen and calcium binding EGF domains 1 (CCBE1). After plasmin and ADAMTS3, KLK3 is the third protease shown to activate VEGF-C. Since differently activated VEGF-Cs are characterized by successively shorter N-terminal helices, we created an even shorter hypothetical form, which showed preferential binding to VEGFR-3. Using mass spectrometric analysis of the isolated VEGF-C-cleaving activity from human saliva, we identified cathepsin D as a protease that can activate VEGF-C as well as VEGF-D.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Sawan Kumar Jha

    Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1898-4928

  2. Khushbu Rauniyar

    Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5485-7040

  3. Ewa Chronowska

    Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  4. Kenny Mattonet

    Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9705-8086

  5. Eunice Wairimu Maina

    Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  6. Hannu Koistinen

    Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  7. Ulf-Håkan Stenman

    Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  8. Kari Alitalo

    Wihuri Research Institute, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  9. Michael Jeltsch

    Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland
    For correspondence
    michael@jeltsch.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2890-7790

Funding

Academy of Finland (265982)

  • Michael Jeltsch

European Research Council (Horizon 2020 Research and Innovation programme 743155)

  • Kari Alitalo

Wihuri Research Institute

  • Kari Alitalo

Academy of Finland Centre of Excellence Program 2014-2019 (307366)

  • Kari Alitalo

Novo Nordisk Foundation

  • Kari Alitalo

Cancer Society of Finland

  • Sawan Kumar Jha

Biomedicum Helsinki-säätiö

  • Sawan Kumar Jha

Päivikki and Sakari Sohlberg Foundation

  • Khushbu Rauniyar

Wihuri Research Institute

  • Sawan Kumar Jha

Academy of Finland (272683)

  • Michael Jeltsch

Academy of Finland (273612)

  • Michael Jeltsch

Finnish Foundation for Cardiovascular Research

  • Michael Jeltsch

Academy of Finland (273817)

  • Michael Jeltsch

Jane ja Aatos Erkon Säätiö

  • Michael Jeltsch

Cancer Society of Finland

  • Michael Jeltsch

Magnus Ehrnroothin Säätiö

  • Michael Jeltsch

K Albin Johansson Foundation

  • Michael Jeltsch

Integrated Life Science Doctoral Program

  • Sawan Kumar Jha

Sigrid Jusélius Foundation

  • Hannu Koistinen

Laboratoriolääketieteen edistämissäätiö

  • Hannu Koistinen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments carried out in this study were performed according to guidelines and regulations approved by the National Board for Animal Experiments of the Provincial State Office of Southern Finland (ESAVI/7012/04.10.07/2016).

Copyright

© 2019, Jha et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,304
    views
  • 379
    downloads
  • 33
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sawan Kumar Jha
  2. Khushbu Rauniyar
  3. Ewa Chronowska
  4. Kenny Mattonet
  5. Eunice Wairimu Maina
  6. Hannu Koistinen
  7. Ulf-Håkan Stenman
  8. Kari Alitalo
  9. Michael Jeltsch
(2019)
KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
eLife 8:e44478.
https://doi.org/10.7554/eLife.44478

Share this article

https://doi.org/10.7554/eLife.44478

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Genetics and Genomics

    Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer

    Tackhoon Kim, Byung-Sun Park ... Timothy Lu
    Research Article

    Tyrosine kinases play a crucial role in cell proliferation and survival and are extensively investigated as targets for cancer treatment. However, the efficacy of most tyrosine kinase inhibitors (TKIs) in cancer therapy is limited due to resistance. In this study, we identify a synergistic combination therapy involving TKIs for the treatment of triple negative breast cancer. By employing pairwise tyrosine kinase knockout CRISPR screens, we identify FYN and KDM4 as critical targets whose inhibition enhances the effectiveness of TKIs, such as NVP-ADW742 (IGF-1R inhibitor), gefitinib (EGFR inhibitor), and imatinib (ABL inhibitor) both in vitro and in vivo. Mechanistically, treatment with TKIs upregulates the transcription of KDM4, which in turn demethylates H3K9me3 at FYN enhancer for FYN transcription. This compensatory activation of FYN and KDM4 contributes to the resistance against TKIs. FYN expression is associated with therapy resistance and persistence by demonstrating its upregulation in various experimental models of drug-tolerant persisters and residual disease following targeted therapy, chemotherapy, and radiotherapy. Collectively, our study provides novel targets and mechanistic insights that can guide the development of effective combinatorial targeted therapies, thus maximizing the therapeutic benefits of TKIs.

    1. Cancer Biology
    2. Genetics and Genomics

    Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity

    Hirokazu Kimura, Kamel Lahouel ... Nicholas Jason Roberts
    Research Article

    Interpretation of variants identified during genetic testing is a significant clinical challenge. In this study, we developed a high-throughput CDKN2A functional assay and characterized all possible human CDKN2A missense variants. We found that 17.7% of all missense variants were functionally deleterious. We also used our functional classifications to assess the performance of in silico models that predict the effect of variants, including recently reported models based on machine learning. Notably, we found that all in silico models performed similarly when compared to our functional classifications with accuracies of 39.5–85.4%. Furthermore, while we found that functionally deleterious variants were enriched within ankyrin repeats, we did not identify any residues where all missense variants were functionally deleterious. Our functional classifications are a resource to aid the interpretation of CDKN2A variants and have important implications for the application of variant interpretation guidelines, particularly the use of in silico models for clinical variant interpretation.

    1. Cancer Biology
    2. Developmental Biology

    Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C

    Sara Jaber, Eliana Eldawra ... Franck Toledo
    Research Article

    Missense ‘hotspot’ mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here, we generated Trp53Y217C, a mouse model of the human hotspot mutant TP53Y220C. DNA damage responses were lost in Trp53Y217C/Y217C (Trp53YC/YC) cells, and Trp53YC/YC fibroblasts exhibited increased chromosome instability compared to Trp53-/- cells. Furthermore, Trp53YC/YC male mice died earlier than Trp53-/- males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in Trp53YC/YC thymic cells compared to Trp53-/- cells. Surprisingly, we recovered only one Trp53YC/YC female for 22 Trp53YC/YC males at weaning, a skewed distribution explained by a high frequency of Trp53YC/YC female embryos with exencephaly and the death of most Trp53YC/YC female neonates. Strikingly, however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12), we observed a fivefold increase in the proportion of viable Trp53YC/YC weaned females in their progeny. Together, these data suggest that the p53Y217C mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females.